Articles related to TARGETED THERAPIES

Explore groundbreaking trials from SABCS 2023, revealing the potential of sacituzumab govitecan and datopotamab deruxtecan in enhancing treatment paradigms for metastatic breast cancer, spotlighting pivotal advancements in antibody-drug conjugate therapy.

Explore the transformative potential of antibody-drug conjugates (ADCs) in cancer therapy, offering targeted treatments with reduced side effects. Recent approvals and ongoing trials signify a significant shift towards precision medicine in oncology.

A look into the complexities of managing advanced melanoma with BRAF–MEK inhibitors, highlighting a case study where treatment-induced toxic effects posed significant diagnostic and therapeutic challenges.

In the CodeBreaK 100 study, a lower 240 mg dose of sotorasib demonstrated similar efficacy to the FDA-approved 960 mg dose in treating KRAS G12C–mutated NSCLC, with potentially fewer severe adverse events.

This study highlights repotrectinib’s remarkable efficacy in ROS1 fusion–positive NSCLC, demonstrating a notable response even in patients with the challenging ROS1 G2032R mutation, and presents a new potential standard in targeted lung cancer therapy.

In a novel approach to combat metastatic castration-resistant prostate cancer, ODM-208, targeting cytochrome P450 11A1, has shown promising results in reducing prostate-specific antigens and testosterone levels, offering new hope in a challenging therapeutic area.